10-Q: AbCellera Biologics Reports Q1 2026 Results, Advances Pipeline

AbCellera Biologics Inc. reported its first quarter 2026 financial results, highlighting increased revenue and progress in its internal drug candidate pipeline, particularly with ABCL635.

Summary

• AbCellera Biologics Inc. reported a net loss of $43.2 million for the first quarter ended March 31, 2026, an improvement from the $45.6 million net loss in the same period of 2025.
• Total revenue for the quarter increased to $8.3 million, up from $4.2 million in Q1 2025, driven by a significant rise in research fees.
• Research and development expenses increased by 10% to $46.7 million, largely due to the initiation of clinical trials for ABCL575 and ABCL635.
• Sales, general, and administrative expenses decreased by 35% to $12.3 million, attributed to headcount optimization and a legal settlement.
• The company ended the quarter with $504.7 million in cash, cash equivalents, and marketable securities, sufficient to fund operations for at least the next 36 months.
• Positive interim Phase 1 data for ABCL635 was announced in May 2026, showing potent and sustained reduction in biomarkers, a favorable safety profile, and support for monthly dosing; Phase 2 topline data is anticipated in Q3 2026.
• The Phase 1 clinical trial for ABCL575 is ongoing, with topline data expected in Q4 2026.
• ABCL688 has advanced into IND/CTA-enabling studies, with an anticipated IND/CTA submission in 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth and promising clinical data for ABCL635, despite continued net losses which are typical for the industry.

Positives

• Revenue doubled to $8.3 million in Q1 2026 compared to $4.2 million in Q1 2025.
• Net loss decreased to $43.2 million from $45.6 million year-over-year.
• Significant reduction in SG&A expenses by 35% to $12.3 million.
• Positive interim Phase 1 data for ABCL635, demonstrating target engagement and a favorable safety profile.
• Sufficient liquidity of $504.7 million in cash, cash equivalents, and marketable securities to cover at least 36 months of operations.
• ABCL635 Phase 2 topline data expected in Q3 2026, and ABCL575 Phase 1 topline data expected in Q4 2026.
• ABCL688 advanced to IND/CTA-enabling studies.

Negatives

• Continued net loss of $43.2 million in the quarter.
• Increased R&D expenses to $46.7 million, reflecting ongoing investment in pipeline development.
• Cash and cash equivalents decreased by $51.5 million during the quarter, primarily due to operating activities and investing activities.

Risks

• Incurrence of losses since inception and potential inability to achieve profitability.
• Fluctuations in quarterly and annual operating results making future predictions difficult.
• Uncertainty in the successful development and commercialization of drug candidates.
• Reliance on partners for the successful development and commercialization of discovered antibodies.
• Potential for clinical trial delays or failure to obtain regulatory approval.
• Competition from other companies developing similar therapies.
• Need for future capital raises, which could dilute existing shareholders.
• Volatility in the market price of common shares, influenced by clinical milestones and market reactions.
• Potential for impairment charges on goodwill or intangible assets.
• The company has no marketed proprietary drugs and has not independently started late-stage clinical development.

Future Outlook

The company expects to continue significant investments in research and development, potentially leading to further operating losses. However, with $504.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, AbCellera believes it has sufficient liquidity to meet its working capital and capital expenditure needs for at least the next 36 months. The company anticipates a reduction in investing cash outflows following the completion of its clinical manufacturing facility and corporate headquarters.

Management Comments

• The company is leveraging its platform to develop internal programs and advance a pipeline of AbCellera-led programs with first-in-class potential.
• Expects to continue making significant investments in research and development activities, advancing internal programs, improving operations, and defending intellectual property.
• The company substantially completed its final large platform investments in its clinical manufacturing facility and corporate headquarters in 2025, shifting capital allocation to using these capabilities.

Industry Context

StockSavvy.ai notes that AbCellera's Q1 2026 results reflect the typical investment cycle in the biotechnology sector, with increased R&D spending to advance drug candidates through clinical trials. The positive interim data for ABCL635 is a key development that will be closely watched by investors and competitors.

Legal Proceedings

• The company is involved in a lawsuit filed on October 14, 2022, by the Estate of John Schrader and ImmVivos Pharmaceuticals Inc., alleging breach of implied partnership/joint venture and patent infringement. The company believes the claim is meritless and is seeking dismissal of certain affiliates for lack of jurisdiction.

Stakeholder Impact

• Shareholders may see potential value appreciation if clinical trials for ABCL635 and ABCL575 are successful.
• Employees will continue to be key to advancing the company's pipeline and capabilities.
• Partners are crucial for the downstream success of discovered antibodies, impacting future milestone and royalty payments.

Next Steps

• Continue enrolling patients in the Phase 2 study for ABCL635.
• Anticipate topline data readout for ABCL635 Phase 2 in Q3 2026.
• Anticipate topline data readout for ABCL575 Phase 1 in Q4 2026.
• Submit IND/CTA for ABCL688 in 2027.
• Optimize long-term office-lease arrangements and assign or fully sublease Beedie JV space.
• Continue investing in research and development to enhance capabilities and advance the internal pipeline.

Key Dates

Recommendation

The company shows progress in its pipeline with positive early clinical data for ABCL635 and a strong cash position. However, the continued net losses, the inherent risks of drug development, and the reliance on future clinical trial success warrant a 'hold' recommendation until more definitive clinical and commercial outcomes are achieved.

Keywords

AbCellera Biologics, 10-Q Filing, Biotechnology, Drug Discovery, Antibody Therapeutics, Clinical Trials, ABCL635, ABCL575, Financial Results, SEC Filing